JPMorgan raised the firm’s price target on Edgewise Therapeutics to $30 from $27 and keeps an Overweight rating on the shares following a model update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- TipRanks ‘Perfect 10’ List: 3 Stocks that Analysts Rate a Strong Buy
- Edgewise Therapeutics added to Best Ideas List at Wedbush
- Edgewise Therapeutics participates in a conference call with JPMorgan
- Edgewise Therapeutics management to meet with Piper Sandler
- Edgewise Therapeutics initiated with Not Rated at Goldman Sachs